Wolfe Research Initiates Coverage On Ovid Therapeutics with Outperform Rating, Announces Price Target of $5
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsInitiationPrice Target
Wolfe Research initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Outperform rating and announces Price Target of $5.
Wolfe Research initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Outperform rating and announces Price Target of $5.